Precision BioSciences, Inc. (DTIL)
Nasdaq: DTIL · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2006
Who owns Precision BioSciences, Inc.
As filed with the SECHolders of 5% or more
6
Octagon Capital Advisors LP holds 9.99% of Common Stock, $0.000005 par value, as its SCHEDULE 13G filed Feb 10, 2026 says.
Directors and officers
12
report now, of 26 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Octagon Capital Advisors LP
SCHEDULE 13G · filed Feb 10, 2026 · Common Stock, $0.000005 par value
Matthew Smith
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.000005 per share · 8.9% in Mar 26, 2025
Aberdeen Group plc
SCHEDULE 13G · filed Jan 27, 2026 · Common Stock, par value $0.000005 per share
Bleichroeder LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Shares · 9.69% in Aug 14, 2025
Lynx1 Capital Management LP
SCHEDULE 13G · filed Jul 20, 2026 · Common Stock, par value $0.000005 per share · 4.1% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
Empery Asset Management, LP
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock, $0.000005 par value per share · reported falling below 5%, from 7.63% in Apr 15, 2026
Weinstein Benjamin
SCHEDULE 13G/A · filed Aug 24, 2026 · Common Stock, par value $0.000005 per share · reported falling below 5%, from 5.2% in Mar 18, 2025
Novartis Pharma AG
SCHEDULE 13G/A · filed Aug 6, 2025 · Common stock, par value $0.000005 per share · reported falling below 5%, from 5.4% in Feb 12, 2025
Highbridge Capital Management, LLC
SCHEDULE 13G/A · filed Apr 25, 2025 · Common Stock, par value $0.000005 per share · reported falling below 5%
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.000005 per share · reported falling below 5%, from 6.4% in May 15, 2025
Aquilo Capital, L.P.
SCHEDULE 13G/A · filed Aug 6, 2025 · Common Stock, par value $0.000005 per share · reported falling below 5%, from 9.9% in Feb 14, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What DTIL reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Elo
An investee · investee · invested in, named in the 10-K filed Mar 12, 2026
Insider tradesForm 4
9sales
6purchases
9sales on a scheduled plan
4people selling
$500,000sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO | 2 | $200,000 | 2 | 0 | $0 |
| Kelly John Alexander | Chief Financial Officer | 2 | $100,000 | 2 | 0 | $0 |
| Scimeca Dario | Chief Legal Officer | 3 | $100,000 | 3 | 0 | $0 |
| Smith J. Jefferson | Chief Research Officer | 2 | $100,000 | 2 | 0 | $0 |
| Frankel Stanley | director | 0 | $0 | 0 | 2 | $0 |
| Brown Melinda | director | 0 | $0 | 0 | 2 | $0 |
| Germano Geno J | director | 0 | $0 | 0 | 2 | $0 |